Summary
Stryker Corporation reported strong performance for the fiscal year 2025, with net sales growing by 11.2% to $25,116 million, driven by robust increases in both its MedSurg and Neurotechnology segment (up 15.7%) and its Orthopaedics segment (up 4.3%). This growth was primarily fueled by increased unit volume across all businesses, with a notable contribution from the acquisition of Inari Medical, Inc. The company also demonstrated improved profitability, with gross profit increasing and operating income rising to $4,889 million, reflecting effective pricing strategies and favorable volume dynamics. Financially, Stryker maintained a healthy liquidity position, with significant cash flow from operations and substantial cash reserves. The company continued its capital allocation strategy, investing heavily in acquisitions totaling $4,960 million, while also returning capital to shareholders through dividends. Despite macroeconomic headwinds and ongoing investments in growth initiatives, Stryker has reaffirmed its commitment to innovation and expanding its product offerings, particularly in areas like robotic-assisted surgery and minimally invasive treatments, positioning it for continued success in the dynamic medical technology landscape.
Financial Highlights
51 data points| Revenue | $25.12B |
| Cost of Revenue | $9.05B |
| Gross Profit | $16.07B |
| R&D Expenses | $1.62B |
| SG&A Expenses | $8.65B |
| Operating Expenses | $11.18B |
| Operating Income | $4.89B |
| Interest Expense | $582.00M |
| Net Income | $3.25B |
| EPS (Basic) | $8.49 |
| EPS (Diluted) | $8.40 |
| Shares Outstanding (Basic) | 382.20M |
| Shares Outstanding (Diluted) | 386.50M |
Key Highlights
- 1Stryker achieved a 11.2% increase in reported net sales in 2025, reaching $25,116 million, with organic sales growth of 9.9% when excluding acquisitions and divestitures.
- 2The MedSurg and Neurotechnology segment saw significant growth of 15.7% as reported, driven by strong performance across Instruments, Endoscopy, Medical, and Vascular businesses, including the impact of the Inari acquisition.
- 3The Orthopaedics segment grew 4.3% as reported, with contributions from Knees, Hips, and Trauma and Extremities, despite a slight decrease in price for these products.
- 4Gross profit margin improved to 64.0% in 2025 from 63.9% in 2024, primarily due to higher sales pricing and favorable volume.
- 5Significant strategic investments were made in acquisitions, totaling $4,960 million in 2025, most notably the acquisition of Inari Medical, Inc., enhancing the Vascular business.
- 6Operating income increased by 32.5% to $4,889 million in 2025, showcasing improved operational efficiency and profitability.
- 7The company generated strong net cash from operating activities of $5,044 million, enabling continued investment in growth and shareholder returns.
- 8Stryker's Board of Directors declared a dividend of $3.36 per common share in 2025, reflecting a commitment to shareholder returns.